<?xml version="1.0" encoding="UTF-8"?>
<p>About 40% to 80% of patients with malignant tumors have nutrition-related problems, which are more common in patients with head and neck tumors and digestive tract tumors,
 <sup>[
  <xref rid="R1" ref-type="bibr">1</xref>]
 </sup> and the patients with esophageal cancer have a higher incidence of malnutrition. It is reported that 60% to 85% of patients with esophageal cancer have different degrees of malnutrition, ranking first among all tumors.
 <sup>[
  <xref rid="R2" ref-type="bibr">2</xref>]
 </sup> Malnutrition will affect the therapeutic effect of malignant tumor patients, reduce the quality of life, shorten the survival time, and increase medical expenses.
 <sup>[
  <xref rid="R3" ref-type="bibr">3</xref>,
  <xref rid="R4" ref-type="bibr">4</xref>]
 </sup> According to the guidelines on enteral nutrition for tumor patients issued by the European Society of Enteral and Parenteral Nutrition in 2006, oral nutrition supplement (ONS) is recommended as the first choice of nutritional support for radiotherapy patients.
 <sup>[
  <xref rid="R5" ref-type="bibr">5</xref>]
 </sup> ONS is also recommended as the first choice of enteral nutrition in the consensus of Chinese experts on enteral nutrition for radiotherapy patients with esophageal cancer undergoing radiotherapy.
 <sup>[
  <xref rid="R6" ref-type="bibr">6</xref>]
 </sup>
</p>
